OVERVIEW

Cancer Summaries and Commentaries™: Update from Barcelona: Advances in the Treatment of Breast Cancer is organized by Physicians' Education Resource, LLC (PER).

Release Date: December 23, 2019
Expiration Date: December 23, 2020

Accreditation:
Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Activity Overview:
This online activity is designed to update physicians on data presented at the European Society for Medical Oncology (ESMO) Annual Meeting, held in September 2019 in Barcelona, Spain. Cancer Summaries and Commentaries™: Update From Barcelona: Advances in the Treatment of Breast Cancer online continuing medical education (CME) activity facilitates critical assessment and clinical integration of new evidence, when appropriate. This activity reviews 4 late-breaking abstracts with some of the most compelling and clinically relevant breast cancer presentations from the meeting. For each abstract, a short summary of key clinical data is accompanied by expert perspectives that provide insight into how clinicians can apply these findings to their clinical practice to improve patient care.

Learning Objectives:
Upon successful completion of this educational activity, you should be better prepared to:
• Outline testing methods that allow for optimized characterization of tumor biology among patients with breast cancer
• Explain the study design, rationale, and results of recent clinical trials evaluating novel strategies for breast cancer treatment
• Consider recent evidence in the context of evolving treatment paradigms in the field of breast cancer management

Benefits of Participating:
• Hear from the experts about recent clinical trials in HR-positive (+)/HER2-negative (–) advanced breast cancer; early-stage, triple-negative breast cancer; and germline BRCA1/2-mutated metastatic/advanced breast cancer and their impact on clinical practice decisions
• Identify opportunities to implement emerging treatments for the management of HR+/HER2– advanced breast cancer; early-stage, triple-negative breast cancer; and germline BRCA1/2-mutated metastatic/advanced breast cancer
• Explore the role of PARP inhibitors and immunotherapy in the treatment and management of breast cancer